rovunaptabin
Phase 2- Indications
- Post-COVID syndrome, Dilated cardiomyopathy
Company intelligence / Profile preview
Berlin Cures
Berlin, Berlin, Germanyberlincures.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Phase 2
01
Overview
Topline results of Phase 2 Long Covid trial did not show evidence of superior efficacy of BC 007 over placebo arm. In a Phase IIa trial for heart failure, BC 007 demonstrated long-term autoantibody neutralization after a single dose resulting in significant improvement in cardiac function.
- Therapeutic areas
- OphthalmologyImmunologyCardiovascularInfectious Diseases
- Modalities
- DNA aptamers
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Uniklinikum Erlangen
Beyond the preview
Go deeper on Berlin Cures.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Berlin Cures.